全文获取类型
收费全文 | 3395篇 |
免费 | 261篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 73篇 |
妇产科学 | 75篇 |
基础医学 | 373篇 |
口腔科学 | 35篇 |
临床医学 | 549篇 |
内科学 | 598篇 |
皮肤病学 | 93篇 |
神经病学 | 400篇 |
特种医学 | 89篇 |
外科学 | 376篇 |
综合类 | 98篇 |
一般理论 | 4篇 |
预防医学 | 503篇 |
眼科学 | 50篇 |
药学 | 233篇 |
中国医学 | 9篇 |
肿瘤学 | 137篇 |
出版年
2023年 | 31篇 |
2022年 | 17篇 |
2021年 | 57篇 |
2020年 | 44篇 |
2019年 | 63篇 |
2018年 | 77篇 |
2017年 | 68篇 |
2016年 | 80篇 |
2015年 | 104篇 |
2014年 | 126篇 |
2013年 | 169篇 |
2012年 | 246篇 |
2011年 | 263篇 |
2010年 | 156篇 |
2009年 | 150篇 |
2008年 | 242篇 |
2007年 | 220篇 |
2006年 | 224篇 |
2005年 | 205篇 |
2004年 | 175篇 |
2003年 | 157篇 |
2002年 | 141篇 |
2001年 | 42篇 |
2000年 | 33篇 |
1999年 | 46篇 |
1998年 | 50篇 |
1997年 | 33篇 |
1996年 | 38篇 |
1995年 | 39篇 |
1994年 | 25篇 |
1993年 | 26篇 |
1992年 | 27篇 |
1991年 | 16篇 |
1990年 | 11篇 |
1989年 | 14篇 |
1988年 | 16篇 |
1987年 | 22篇 |
1986年 | 26篇 |
1985年 | 16篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1982年 | 18篇 |
1981年 | 18篇 |
1980年 | 20篇 |
1979年 | 11篇 |
1978年 | 9篇 |
1977年 | 16篇 |
1976年 | 11篇 |
1973年 | 8篇 |
1966年 | 7篇 |
排序方式: 共有3709条查询结果,搜索用时 31 毫秒
91.
92.
93.
Rhinitis is normally defined by the symptoms of nasal congestion, postnasal drainage, rhinorrhea, and sneezing. It has been associated with various pathologic changes, but can occur in the absence of any inflammation. Thus, the diagnosis is based on the clinical presentation. There are no clear-cut criteria to distinguish when rhinitis becomes chronic, but in its chronic form, it can be complex. Chronic forms of rhinitis that occur in the absence of any detectable specific IgE against relevant aeroallergens in its broadest sense can be called chronic nonallergic rhinitis. This review will concentrate on chronic nonallergic rhinitis in its various forms, discussing the epidemiology, underlying mechanisms, and its therapy. 相似文献
94.
Jae Phil Na Kyu Chul Shin Seunghwan Kim Yoo Seok Park Sung Phil Chung In Cheol Park Joon Min Park Min Joung Kim 《Yonsei medical journal》2014,55(3):617-624
Purpose
ST-elevation myocardial infarction (STEMI) patients may visit the emergency department (ED) complaining of sensations of pain other than the chest. We investigated our performance of reperfusion therapy for STEMI patients presenting with non-chest pains.Materials and Methods
This was a retrospective observational cohort study. STEMI patients who underwent primary percutaneous coronary intervention (PCI) were divided into a chest pain group and a non-chest pain group. Clinical differences between the two groups and the influence of presenting with non-chest pains on door-to-electrocardiograms (ECG) time, door-to-balloon time, and hospital mortality were evaluated.Results
Of the 513 patients diagnosed with STEMI, 93 patients presented with non-chest pains. Patients in the non-chest pain group were older, more often female, and had a longer symptom onset to ED arrival time and higher Killip class than patients in the chest pain group. There was a statistically significant delay in door-to-ECG time (median, 2.0 min vs. 5.0 min; p<0.001) and door-to-balloon time (median, 57.5 min vs. 65.0 min; p<0.001) in patients without chest pain. In multivariate analysis, presenting with non-chest pains was an independent predictor for hospital mortality (odds ratio, 2.3; 95% confidence interval, 1.1-4.7). However, door-to-ECG time and door-to-balloon time were not factors related to hospital mortality.Conclusion
STEMI patients presenting without chest pain showed higher baseline risk and hospital mortality than patients presenting with chest pain. ECG acquisition and primary PCI was delayed for patients presenting with non-chest pains, but not influencing hospital mortality. Efforts to reduce pre-hospital time delay for these patients are necessary. 相似文献95.
Katja M. Shimko Jake W. O'Brien Leon Barron Hasan Kayalar Jochen F. Mueller Ben J. Tscharke Phil M. Choi Hui Jiang Geoff Eaglesham Kevin V. Thomas 《Drug testing and analysis》2019,11(7):937-949
Anabolic‐androgenic steroids are synthetic compounds prohibited due to their performance‐enhancing characteristics. The use of these substances is known to cause health‐related issues, which highlights the importance of being able to evaluate the scale of consumption by the general population. However, most available research on the analysis of anabolic steroids is focused on animals and athletes in connection with doping. The potential of wastewater‐based epidemiology as an intelligence tool for the assessment of community level use of anabolic steroids is presented herein. A liquid chromatography tandem mass spectrometry method was developed for the analysis of 10 anabolic‐androgenic steroids and 14 endogenous hormones in influent wastewater. The validated method was applied to sixteen 24‐hour composite wastewater influent samples that were collected over a period of five years from two wastewater treatment plants in Queensland, Australia. Nine investigated compounds were found to be present at concentrations between 14 and 611 ng L?1 which translated into 3–104 mg excreted per 1000 individuals per day. It was concluded that the developed analytical method is suitable for the analysis of AAS in wastewater matrix. Additionally, both the inclusion of metabolites and further investigation into deconjugation by enzymatic hydrolysis would aid in understanding and evaluating community anabolic steroid use. For the first time, this study presents the application of wastewater‐based epidemiology on anabolic‐androgenic steroids in Australia. 相似文献
96.
97.
DHANUNJAYA LAKKIREDDY M.D. ARUN KANMANTHAREDDY M.D. MAZDA BIRIA M.D. YERUVA MADHU REDDY M.D. JAYASREE PILLARISETTI M.D. SRIJOY MAHAPATRA M.D. LOREN BERENBOM M.D. LARRY CHINITZ M.D. DONITA ATKINS R.N. SUDHARANI BOMMANA M.Phil. RODERICK TUNG M.D. LUIGI DI BIASE M.D. KALYANAM SHIVKUMAR M.D. ANDREA NATALE M.D. 《Journal of cardiovascular electrophysiology》2014,25(7):739-746
98.
Kerstin Hogg Joseph Shaw Douglas Coyle Parvaneh Fallah Marc Carrier Phil Wells 《Thrombosis research》2014
Introduction
The standard gamble is considered the ‘gold standard’ technique for measuring quality of life. We recently used the standard gamble to estimate quality of life in acute venous thrombosis, and found unexpected variability in the responses. The current study aimed to explore the reasons for variability by comparing the standard gamble technique in patients with acute venous thrombosis to other quality of life measurement tools.Materials and Methods
Thrombosis clinic patients treated for venous thrombosis were eligible to participate. Patients evaluated their current health state by performing a standard gamble interview, reporting on a visual analogue scale, completing the SF-36 and disease specific questionnaires (PEmb-Qol and VEINES-QOL/Sym). Validity was assessed by correlating the standard gamble utilities with the other methods. Test-retest reliability, responsiveness and acceptability were also assessed.Results
Forty-four patients were interviewed, with 16 attending for a repeat interview. The median standard gamble utility was 0.97 (0.84-1.0), SF-6D 0.64 (0.59 - 0.80) and visual analogue score 70 (60 - 80). Participants with pulmonary embolism had lower standard gamble estimates than those with deep vein thrombosis. There was good discriminant validity in that the standard gamble estimates were not associated with risk taking behavior, negative outlook, sex or education. Test-retest reliability with the standard gamble was moderate and there was evidence of a ceiling effect.Conclusions
Standard gamble utilities are higher than other methods of measuring quality of life in venous thrombosis. The choice of utility values adopted in studies will impact on future economic studies. 相似文献99.
100.
Lown MT Munyombwe T Harrison W West RM Hall CA Morrell C Jackson BM Sapsford RJ Kilcullen N Pepper CB Batin PD Hall AS Gale CP;Evaluation of Methods Management of Acute Coronary Events 《The American journal of cardiology》2012,109(3):307-313
Risk assessment is central to the management of acute coronary syndromes. Often, however, assessment is not complete until the troponin concentration is available. Using 2 multicenter prospective observational studies (Evaluation of Methods and Management of Acute Coronary Events [EMMACE] 2, test cohort, 1,843 patients; and EMMACE-1, validation cohort, 550 patients) of unselected patients with acute coronary syndromes, a point-of-admission risk stratification tool using frontal QRS-T angle derived from automated measurements and age for the prediction of 30-day and 2-year mortality was evaluated. Two-year mortality was lowest in patients with frontal QRS-T angles <38° and highest in patients with frontal QRS-T angles >104° (44.7% vs 14.8%, p <0.001). Increasing frontal QRS-T angle-age risk (FAAR) scores were associated with increasing 30-day and 2-year mortality (for 2-year mortality, score 0 = 3.7%, score 4 = 57%; p <0.001). The FAAR score was a good discriminator of mortality (C statistics 0.74 [95% confidence interval 0.71 to 0.78] at 30 days and 0.77 [95% confidence interval 0.75 to 0.79] at 2 years), maintained its performance in the EMMACE-1 cohort at 30 days (C statistics 0.76 (95% confidence interval 0.71 to 0.8] at 30 days and 0.79 (95% confidence interval 0.75 to 0.83] at 2 years), in men and women, in ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, and compared favorably with the Global Registry of Acute Coronary Events (GRACE) score. The integrated discrimination improvement (age to FAAR score at 30 days and at 2 years in EMMACE-1 and EMMACE-2) was p <0.001. In conclusion, the FAAR score is a point-of-admission risk tool that predicts 30-day and 2-year mortality from 2 variables across a spectrum of patients with acute coronary syndromes. It does not require the results of biomarker assays or rely on the subjective interpretation of electrocardiograms. 相似文献